These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30707922)

  • 41. Evaluation of the immunogenicity and efficacy of a chimeric OMP25-OMP31 antigen in BALB/c mice.
    Mohammadi Y
    Vet Med Sci; 2021 Sep; 7(5):2008-2014. PubMed ID: 34057317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections.
    Abkar M; Amani J; Sahebghadam Lotfi A; Nikbakht Brujeni G; Alamian S; Kamali M
    APMIS; 2015 Aug; 123(8):667-75. PubMed ID: 25939375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and
    Harzandi N; Aghababa H; Khoramabadi N; Tabaraie T
    Iran J Biotechnol; 2021 Jan; 19(1):e2618. PubMed ID: 34179193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of an immuno-dominant antigen in Brucella ovis and evaluation of its use in an enzyme-linked immunosorbent assay.
    Kittelberger R; Diack DS; Vizcaíno N; Zygmunt MS; Cloeckaert A
    Vet Microbiol; 1998 Jan; 59(2-3):213-27. PubMed ID: 9549861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
    Mailybayeva A; Yespembetov B; Ryskeldinova S; Zinina N; Sansyzbay A; Renukaradhya GJ; Petrovsky N; Tabynov K
    PLoS One; 2017; 12(10):e0186484. PubMed ID: 29023541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A; Abbady AQ
    J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of potential antigens from non-classically secreted proteins and designing novel multitope peptide vaccine candidate against Brucella melitensis through reverse vaccinology and immunoinformatics approach.
    Vishnu US; Sankarasubramanian J; Gunasekaran P; Rajendhran J
    Infect Genet Evol; 2017 Nov; 55():151-158. PubMed ID: 28919551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice.
    Vitry MA; De Trez C; Goriely S; Dumoutier L; Akira S; Ryffel B; Carlier Y; Letesson JJ; Muraille E
    Infect Immun; 2012 Dec; 80(12):4271-80. PubMed ID: 23006848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.
    Zhang J; Yin S; Yi D; Zhang H; Li Z; Guo F; Chen C; Fang W; Wang J
    Microb Pathog; 2017 Nov; 112():148-155. PubMed ID: 28916316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2015 Oct; 33(42):5532-5538. PubMed ID: 26384448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+rP39) against B. abortus 544 and B. melitensis 16M infection in murine model.
    Tadepalli G; Singh AK; Balakrishna K; Murali HS; Batra HV
    Mol Immunol; 2016 Mar; 71():34-41. PubMed ID: 26826463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and Production of a Novel Recombinant Chimeric IL2-Omp31 Antigen against Brucella Infection.
    Naghavi M; Sekhavati MH; Tahmoorespur M; Nassiri MR
    Arch Razi Inst; 2018 Sep; 73(3):199-206. PubMed ID: 30280839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein.
    Vizcaíno N; Cloeckaert A; Zygmunt MS; Dubray G
    Infect Immun; 1996 Sep; 64(9):3744-51. PubMed ID: 8751924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omp31 plays an important role on outer membrane properties and intracellular survival of Brucella melitensis in murine macrophages and HeLa cells.
    Verdiguel-Fernández L; Oropeza-Navarro R; Basurto-Alcántara FJ; Castañeda-Ramírez A; Verdugo-Rodríguez A
    Arch Microbiol; 2017 Sep; 199(7):971-978. PubMed ID: 28382472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of recombinant Escherichia coli expressing the omp31 gene of Brucella melitensis in BALB/c mice.
    Guilloteau LA; Laroucau K; Vizcaíno N; Jacques I; Dubray G
    Vaccine; 1999 Jan; 17(4):353-61. PubMed ID: 9987174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
    Jain-Gupta N; Contreras-Rodriguez A; Vemulapalli R; Witonsky SG; Boyle SM; Sriranganathan N
    FEMS Immunol Med Microbiol; 2012 Dec; 66(3):436-44. PubMed ID: 23163875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.
    Bhattacharjee AK; Van de Verg L; Izadjoo MJ; Yuan L; Hadfield TL; Zollinger WD; Hoover DL
    Infect Immun; 2002 Jul; 70(7):3324-9. PubMed ID: 12065469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challenge.
    Clapp B; Yang X; Thornburg T; Walters N; Pascual DW
    Immunol Cell Biol; 2016 May; 94(5):496-508. PubMed ID: 26752510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-γ and IL-12p70 protective immune response in BALB/c mice against virulent Brucella.
    Tadepalli G; Konduru B; Murali HS; Batra HV
    Immunol Lett; 2017 Dec; 192():79-87. PubMed ID: 29106986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.